Beneficial effects of a diet rich in a mixture of n - 6/n - 3 essential fatty acids and of their metabolites on cyclosporine - nephrotoxicity

Journal of Nutritional Biochemistry

Volumn 14, Issue 8, 2003, Pages 480-486

  Tsipas, George ^a,b   Morphake, Polymnia ^b  

^a UNIVERSITY OF IOANNINA   (Greece)

^b General Hospital of Agrinio   (Greece)

Author keywords

Cyclosporine; N 3 essential fatty acids; N 6; Nephrotoxicity; Prostaglandins; Thromboxanes

Indexed keywords

ARACHIDONIC ACID DERIVATIVE; CREATININE; CYCLOSPORIN; ESSENTIAL FATTY ACID; FISH OIL; OMEGA 3 FATTY ACID; OMEGA 6 FATTY ACID; PRIMROSE OIL; PROSTACYCLIN; PROSTAGLANDIN E; THROMBOXANE A2; THROMBOXANE B2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DIET; EXPERIMENTAL MODEL; FAT INTAKE; FEMALE; HISTOPATHOLOGY; KIDNEY FUNCTION; KIDNEY TUBULE DISORDER; METABOLITE; MICROSCOPY; NEPHROTOXICITY; NONHUMAN; PROPHYLAXIS; PROSTAGLANDIN SYNTHESIS; PROTEIN URINE LEVEL; PROTEINURIA; RAT; URINALYSIS; URINARY EXCRETION; URINE VOLUME; WEIGHT REDUCTION;

ANIMALIA;

EID: 0042977419     PISSN: 09552863     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-2863(03)00102-5     Document Type: Article

References (56)

1. Azou B.L.́, Azou J., Medina W., Frieauff W., Cordier A., Cambar J., Wolf A. In vitro models to study mechanisms involved in cyclosporine A-mediated glomerular contraction. Arch Tox. 73:(8-9):1999;337-345.
2. Myers B.D. Cyclosporine nephrotoxicity. Kidney Intl. 30:1986;964-967.
3. Rush D.N. Cyclosporine toxicity to organs other than the kidney. Clin Biochem. 14:1991;101-105.
4. McCauley J., Bronsther O., Fung J., Starzl T.E. Treatment of cyclosporin - induced haemolytic uraemic syndrome with FK 506. Lancet. 2:1989;1516.
5. Mihatsch M.J., Thirl G., Ryffel B. Morphology of cyclosporin nephropathy. Prog Allergy. 38:1986;447-450.
6. Bennett W.M., Elzinga L., Kelley V. Pathophysiology of cyclosporine nephrotoxicity. Role of eicosanoids. Transplant Proc. XX:(supp 3):1988;628-633.
7. Bennett W.M. Mechanisms of acute and chronic nephrotoxicity from immunosuppressive drugs. Renal Failure. 18:(3):1996;453-460.
8. Ryffel B., Foxwell M.B., Gee A., Greiner B., Woerly G., Mihatsch J.M. Cyclosporine-relationship of side effects to mode of action. Transplantation. 46:1988;90S-96S.
9. Lusting S., Stem N., Eggena P. Effect of cyclosporin on blood pressure and renin - angiotensin axis in rats. Am J Physiol. 253:1987;H1596-H1600.
10. Colub M.S., Berger M.E. Direct augmentation by cyclosporin A of the vascular contractile response to nerve stimulation. Hypertension. 9:(supp III):1987;96-100.
11. Coffman T.M., Carr D.R., Yarger W.E., Klotman P.E. Evidence that renal prostaglandin and thromboxane production by chronic cyclosporine nephro-toxicity. Transpl. 43:1987;282-285.
12. Tsipas G., Morphake P., Darlametsos I., Bariety J., Gkika E.L., Hornych A., Manos G., Papanikolaou N.A selective TXA - synthetase inhibitor, OKY-046, partially protected rats against the nephrotoxicity induced by cyclosporine. Proceedings 3rd International Satelite Symposium on acute renal failure. University Studio Press, Halkidiki, Greece, 1993. pp 277-89.
13. Darlametsos I., Morphake P., Bariety J., Hornych A., Tsipas G., Gkikas G., Papanikolaou N. Effect of Ketanserine in cyclosporine-induced renal dysfunction in rats. Nephron. 70:1995;249-254.
14. Copeland K.R., Yatscoff R.W. Comparison of the effects of cyclosporine and its metabolites on the release of prostacyclin and endothelin from mesangial cells. Transplantation. 53:(3):1992;640-645.
15. Papanikolaou N., Darlametsos I., Tsipas G., Morphake P., Bokas S., Gkikas G., Hornych A., Bariety J., Gkika E.L., Karageorgou I., Patsialos K. Effects of OKY-046 and nifedipine in CsA-induced renal dysfunction in rats. Prostagl Leuk and Essential Fatty Acids. 55:1996;249-256.
16. 2 by the kidney in the glycerol-induced acute renal failure in rabbit. Prostaglandins. 19:1980;333-337.
17. 2-synthetase OKY-046. Experientia. 42:1986;613-615.
18. Papanikolaou N., Chatziantoniou C., Dontas A., Gkika E.L., Paris M., Gkikas G., Bariety J. Is thromboxane a potent antinatriuretic factor and is it involved in the development of acute renal failure? Nephron. 45:1987;277-282.
19. 2-induced autoimmune glomerulonephritis and A.R.F. in Brown Norway rats. Omega-6 essential fatty acids. Liss A., New York, 1990. pp. 391-412.
20. 2? Prostagl Leuk and Essential Fatty Acids. 45:1992;131-136.
21. Grauer G.F., Greco D.S., Behrend E.N., Fettman M.J., Mani I., Getzy D.M., Reinhart G.A. Effects of dietary n - 3 fatty acid supplementation versus thromboxane synthetase inhibition on gentamicin-induced nephrotoxicosis in healthy male dogs. Am J Vet Res. 57:(6):1996;948-956.
22. Mendal A., Miller J. Protection against ischemic acute renal failure by prostaglandin infusion. Prostaglandins Leuk Med. 8:1982;361-373.
23. 2 attenuates ischemic acute renal failure in the rat. Am J Physiology. 247:1884;F714-F717.
24. Crafa F., Gugenheim J., Saintpaul M.C., Cavanel C., Lapalus F., Ouzan D., Militerno G., Mouiel J. Protective effects of prostaglandin E (1) on normo-thermic liver inchemia. Eur Surg Res. 23:(5-6):1991;278-284.
25. Morphake P., Bariety J., Darlametsos I., Tsipas G., Gkikas G., Hornych A., Papanikolaou N. Alteration of cyclosporine-induced nephrotoxicity by gamma linolenic (GLA) acid and eicosapentaenoic acid (EPA) in Wistar rats. Prostag Leuk and Essential Fatty Acids. 50:1994;29-35.
26. Hardy G., Stanke-Labesque F., Deveaux G., Devillier P., Sessa C., Bessard G. Cyclosporine A and Cremophor EL induce contractions of humman saphenous vein involvement of thromboxane A (2) receptor-dependent pathway . J Cardiov Pharm. 36:(6):2000;693-698.
27. Parra T., de Arriba G., de Lema G.P., Rodriguez-Puyol D., Rodriguez-Puyol M. Cyclosporine a nephrotoxicity Role of thromboxane and reactive oxygen species . J Lab Clin Med. 131:1998;63-70.
28. Sprecher H. Metabolism of highly unsaturated n-3 and n-6 fatty acids. Biochim Biophys Acta. 1486:(2-3):2000;219-231.
29. Horrobin F.D. GLA an interediate in essential fatty acid metabolism with potential as an ethical pharmaceutical and as a food . Rev Contemp Pharmacoth. 1:1990;1-45.
30. Euang Y.S., Smith R.S., Redden P.R., Cantrill R.C., Horrobin D.F. Modification of liver fatty acid metabilism in mice by n - 3 and n - 6 delta-6-desaturase substrates and products. Biochimica et Biophysica Acta. 1082:(3):1991;319-327.
31. Nassar B.A., Huang Y.S. The influence of dietary manipulation with n - 3 and n - 6 fatty acids on liver and plasma phospolipid fatty in rats. Lipids. 21:1986;652-656.
32. Cleland G.L., Gibson A.R., Neumann M., French K.J. The effect of dietary fish oil supplement upon the content of DGLA in Human plasma phosoholipids. Prost Leuk and Essential Fatty Acids. 40:1990;9-12.
33. Manku M.S., Morse-Fisher N., Horrobin D.F. Changes in human plasma essential fatty acid levels as a result of administration of linoleic acid and gamma-linolenic acid. Eur J Nutr. 42:1988;55-60.
34. Arntzen K.J., Brekke O.L., Vatten L., Austgulen R. Reduced production of PGE (2) and PGF (2 alpha) from decidual cell cultures supplemented with n-3 Polyunsaturated fatty acids. Prostagl & Other Lipid Med. 56:(2-3):1998;183-195.
35. Yeo Y.K., Lim A.Y., Lee J.Y., Kim H.J., Farkas T., Kim D. Eicosapentaenoic and docosahexaenoic acids reduce arachidonic acid release by rat kidney microsomes. J Biochem Mol Biol. 32:(1):1999;33-38.
36. Bell J.G., Tocher D.R., Macdonald F.M., Sargent J.R. Effects of diets rich in linoleic (18/2 n-6) and alpha linolenic (18/3 n - 3) acids on the growth, lipid class and fatty-acids compositions and eicosanoid production in juvenile turbot (Scophathalmus-maximus L). Fish Physiol and Bioch. 13:(2):1994;105-118.
37. Stone K.J., Willis A.L., Hart M., Kirtland S.J., Kernoff P.B.A., McNicol G.P. The metabolism of dihomo-g-linolenic acid in man. Lipids. 14:(2):1979;174-180.
38. Fan Y.Y., Chapkin R.S. Phospholipid sources of metabolically elongated gamma- linolenic acid-conversion to prostaglandin - E (1) in stimulated mouse macrophages. J Nutr Biochem. 4:1993;602-607.
39. 2 reduces nephrotoxicity and immunosuppression of cyclosporine in rats. Clin Nephrol. 25:1986;S95-S99.
40. 1. J Urol. 159:(6):1998;1927-1930.
41. Needleman P., Raz A., Minkes M.S., Ferrendelli A., Sprecher H. Triene prostaglandins prostacyclin and thromboxane biosynthesis and unique biological properties . Proc Natl Acad Sci (USA). 76:1979;944-947.
42. 3 in the marmoset monkey (Callithrix jacchus) following dietary supplementation with tuna fish oil. Biochem Biophys Acta. 1003:1989;161-166.
43. 2 formation and fatty acid composition of platelet phospholipids. Am J Nutrition. 14:1991;351-359.
44. Hishinma T., Yamazaki T., Mizugaki M. Effects of long-term supplementation of eicosapentanoic and docosahexanoic acid on the 2-, 3-series prostacyclin production by endothelial cells. Prostagl & Other Lipid Med. 57:(5-6):1999;333-340.
45. 1, infusion therapy in chronic glomerulonephritis-a double-blind, crossover trial. Prostagl Leukot Med. 19:1985;227.
46. 1 in Brown Norway rats with mercury induced autoimmune disease. Clin Immun Immunop. 40:1986;401-409.
47. Hamazaki T., Fischer S., Urakaze M., Sawazaki S., Yano S. Comparison of the urinary metabolites of prostaglandin and thromboxane of the 2- and 3-series in a Japanese fishing and a Japanese farming village. Prostaglandins. 32:1986;655-664.
48. Achard F., Gilbert M., Benistant C., Ben Slama S., DeWitt D.L., Smith W.L., Lagarde M. Eicosapentanoic and docosahexaenoic acids reduce PGH Synthase 1 expression in bovine aortic endothelial cells. Bioch and Bioph Res Commun. 241:(2):1997;513-518.
49. Benistant C., Achard F., Slama S.B., Lagarde M. Docosapentaenoic acid (22:5, n - 3) Metabolism and effect on prostacyclin production in the endothelial cells . Prostagl Leuk and Essential Fatty Acids. 55:(4):1996;287-292.
50. Nieuwenhuys CMA, Feijge MAH, Offermans RFG, Kester ADM, Hornstra G, JWM. Modulation of rat platelet activation by vessel wall-derived prostaglandin and platelet-derived thromboxane: effect of dietary fish oil on thromboxane-prostaglandin balance. Atherosclerosis 2001;154(2):355-66.
51. Elzinga L., Kelley V.E., Houghton D.C., Bennett M.W. Modification of experimental nephrotoxicity with fish oil as a vehicle for cyclosporine. Transplantation. 43:(2):1987;271-274.
52. Homan van der Heide J.J., Hilo H., Donker J.M., Wilmink J.M., Tegzess A.M. Effect of dietary fish oil on renal function and rejection in cyclosporine-treated recipients of renal transplants. New Engl J Med. 329:(11):1993;769-773.
53. Santos J., Queiros J., Silva F., Cabrita A., Rodrigues A., Henriques A.C., Sarmento A.M., Pereira M.C., Guimaraes S. Effects of fish oil in cyclosporine-treated renal transplant recipients. Transplantation Proc. 32:(8):2000;2605-2608.
54. Rubanui G.M., Parker Botelho L.H. Endothelins. FASEB J. 5:1991;2713.
55. Fried G., Samuelsson U. Endothelin and neuropeptide Y are vasoconstrictors in human uterine blood vessels. Am J Obstet Gynecol. 164:1991;1330.
56. Blank M.A., Fuortes M., Nyren O., Jaffe B.M. Effect of endothelin - 1 and vasoactive intestinal polypeptide in the feline colon. Life Sci. 48:1991;1937.